Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | microsomal glutathione s-transferase | 0.0393 | 0.5 | 0.5 |
Schistosoma mansoni | membrane associated proteins in eicosanoid and glutathione metabolism family member | 0.0393 | 0.5 | 0.5 |
Toxoplasma gondii | MAPEG family protein | 0.0393 | 0.5 | 0.5 |
Echinococcus multilocularis | microsomal glutathione S transferase 3 | 0.0393 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 0.5 uM | Antiviral activity against wild type HIV1 NL4-3 in MT4 cells after 5 days by MTT method | ChEMBL. | 18052319 |
EC50 (functional) | = 24.84 uM | Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells after 5 days by MTT method | ChEMBL. | 18052319 |
EC50 (functional) | = 33.55 uM | Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells after 5 days by MTT method | ChEMBL. | 18052319 |
EC50 (functional) | > 54.47 uM | Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells after 5 days by MTT method | ChEMBL. | 18052319 |
ID50 (binding) | = 0.005 uM | Antiviral activity against wild type HIV1 reverse transcriptase | ChEMBL. | 18052319 |
ID50 (binding) | = 0.005 uM | Antiviral activity against wild type HIV1 reverse transcriptase | ChEMBL. | 18052319 |
ID50 (binding) | > 20 uM | Antiviral activity against HIV1 reverse transcriptase K103N mutant | ChEMBL. | 18052319 |
ID50 (binding) | > 20 uM | Antiviral activity against HIV1 reverse transcriptase Y181I mutant | ChEMBL. | 18052319 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.